Publications

5891 Results

Molecular marker analysis of SWOG S0636, a phase II trial of erlotinib and bevacizumab in never-smokers with advanced NSCLC

Authors
PC Mack;J Moon;H West;W Franklin;M Varella-Garcia;M Wynes;A Wozniak;M Redman;F Hirsch;D Gandara
Journal / Conference
J Clin Oncol 30, 2012 (suppl; abstr 7552); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0636

SWOG S0635 and S0636: Phase II Trials of Erlotinib (OSI-774)(E) and Bevacizumab (B) in Advanced (Adv) Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features (adenoBAC), or in Never-Smokers with Primary Adv NSCLC Adenocarcinoma (adenoCa)

Authors
H West;J Moon;F Hirsch;PC Mack;A Wozniak;D Lau;L Fehrenbacher;M Bury;M Redman;D Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7517); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0635, S0636

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) as Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report on the Good Risk Patients

Authors
S Nand;H Gundacker;JE Godwin;C Willman;T Norwood;H Erba;D Howard;S Coutre;M Othus;F Appelbaum
Journal / Conference
J Clin Oncol 30 (suppl; abstr 6502); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Leukemia
Study Number(s)
S0703

Phase I Pharmacokinetic Study of Dasatinib (BMC-354825) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction: S0711, a SWOG Early Therapeutics Committee Study

Authors
J Sarantopoulos;A Hoering;T Synold;D Mahalingam;D Wang;HJ Lenz;P O'Rourke;R Sexton;P Van Veldhuizen;M Mita;L Wong;A Mita;A El-Khoueiry;V Chung;D Gandara;S Tejwan;C Takimoto;P Ivy;R Kurzrock
Journal / Conference
J Clin Oncol 30 (suppl; abstr 3078);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S0711

SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy

Authors
DL Hershman;J Unger;K Crew;C Moinpour;L Minasian;L Hansen;D Lew;P O'Kane;J Wade;S Wong;G Hortobagyi;F Meyskens;K Albain
Journal / Conference
Journal of Clinical Oncology 30 (suppl; abstr 9018);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion (DH unsuccessfully appealed for oral);
Year
2012
Research Committee(s)
Symptom Management and Survivorship
Study Number(s)
S0715

SWOG 0722: A phase II study of mTOR inhibitor everolimus (RAD001) in malignant pleural mesothelioma (MPM)

Authors
L Garland;S-H Ou;J Moon;PC Mack;J Testa;A Tsao;A Wozniak;D Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7083); American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster presentation;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0722

Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib

Authors
PA Philip;B Goldman;R Ramanathan;HJ Lenz;A Lowy;R Whitehead;S Iqbal;R Gaur;J Benedetti;CD Blanke
Journal / Conference
J Clin Oncol 30 (suppl; abstr 4019);American Society of Clinical Oncology 2012 Annual Meeting (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Gastrointestinal
Study Number(s)
S0727

SWOG 0802: A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept) in Patients with Platinum-treated Extensive Stage Small Cell Lung Cancer (E-SCLC)

Authors
J Allen;J Moon;S Gadgeel;K Kelly;PC Mack;H Saba;MK Mohamed;D Gandara
Journal / Conference
J Clin Oncol 30 (suppl; abstr 7005);American Society of Clinical Oncology 2012 Annual Mtg (June 1-5, 2012, Chicago, IL), oral presentation;
Year
2012
Research Committee(s)
Lung
Study Number(s)
S0802

SWOG S0826: A Phase II Trial of SCH 727965 (NSC 747135) in Patients with Stage IV Melanoma

Authors
C Lao;J Moon;J Fruehauf;L Flaherty;M Bury;A Ribas;VK Sondak
Journal / Conference
J Clin Oncol 30 (suppl; abstr 8521); American Society of Clinical Oncology 2012 Annual Mtg (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Melanoma
Study Number(s)
S0826

Randomized phase II study of docetaxel plus vandetanib (V+D) versus docetaxel followed by vandetanib (D --> V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904

Authors
R Coleman;J Moon;A Sood;D Branham;J Delmore;A Bonebrake;G Anderson;D Alberts;M Markman
Journal / Conference
J Clin Oncol 30 (suppl; abstr 5015); American Society of Clinical Oncology 2012 Annual Mtg (June 1-5, 2012, Chicago, IL), poster discussion;
Year
2012
Research Committee(s)
Gynecologic
Study Number(s)
S0904